

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **1** of **6****Complete if Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk, Dale B.
Art Unit	1649
Examiner Name	Daniel E. Kolker
Attorney Docket Number	15270J-004747US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Figures Appear
	945	2008/0050367 A1	02-28-2008	Basi et al.	
	944	2007/0238154 A1	10-11-2007	Basi et al.	
	943	2007/0154480 A1	07-05-2007	Schenk et al.	
	878	7,189,819	03-13-2007	Basi et al.	
	879	7,179,892	02-20-2007	Basi et al.	
	946	2006/0280743 A1	12-14-2006	Basi et al.	
	880	7,014,855	03-21-2006	Schenk	
	881	6,982,084	01-03-2006	Schenk	
	949	2005/0196399 A1	09-08-2005	Schenk et al.	
	892	6,923,964	08-02-2005	Schenk	
	884	2005/0152878 A1	07-14-2005	Solomon et al.	
	882	6,787,139	09-07-2004	Schenk	
	883	6,582,945	06-24-2003	Raso	
	906	6,339,068	01-15-2002	Krieg et al.	
	905	5,994,083	11-30-1999	Felici et al.	
	885	5,798,102	08-25-1998	McMichael et al.	
	924	5,624,937	04-29-1997	Reel et al.	

U.S. PATENT APPLICATIONS

Examiner	Cite No.	Document Number Number Kind Code ² (if known)	Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Figures Appear
	899	11/358,951	02-22-2006	Solomon et al.	
	948	60/251,892	12-06-2000	Basi et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	921	EP	0 391 714	A2	10-10-1990			<input type="checkbox"/>
	935	WO	04/080419	A3	09-23-2004			<input type="checkbox"/>
	918	WO	04/069182	A2	08-19-2004			<input type="checkbox"/>
	934	WO	02/46237	A3	934			<input type="checkbox"/>
	633	WO	96/08565	A2	03-21-1996			<input type="checkbox"/>
	923	WO	95/23860	A2	09-08-1995			<input type="checkbox"/>
	922	WO	94/09364	A1	04-28-1994			<input type="checkbox"/>
	947	WO	92/22653	A1	12-23-1992			<input type="checkbox"/>

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/828,548
		Filing Date	April 19, 2004
		First Named Inventor	Schenk, Dale B.
		Art Unit	1649
		Examiner Name	Daniel E. Kolker
		Attorney Docket Number	15270J-004747US
Sheet	2	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	927	AISEN, P., "Inflammation and Alzheimer's Disease: Mechanisms and Therapeutic Strategies," <u>Gerontology</u> , 43:143-149 (1997).	<input type="checkbox"/>
	912	AKIYAMA et al., "The amino-terminally truncated forms of amyloid β -protein in brain macrophages in the ischemic lesions of Alzheimer's disease patients," <u>Neuroscience Letters</u> , 219:115-118 (1996).	<input type="checkbox"/>
	898	ASKELOF et al., "Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of <i>Bordetella pertussis</i> toxin subunit S1," <u>PNAS</u> , 87:1347-1351 (1990).	<input type="checkbox"/>
	790	BALES et al., "Administration of an Anti-A β Fab Fragment to APP ^{V717F} Transgenic Mice Reduces Neuritic Plaque," Abstract P4-396, presented at Poster Session P4: Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based, <u>Neurology of Aging</u> , 25:S587 (2004).	<input type="checkbox"/>
	911	BEN-YEDIDIA et al., "Design of peptide and polypeptide vaccines," <u>Current Opinion in Biotechnology</u> , 8:442-448 (1997).	<input type="checkbox"/>
	915	BRITT et al., "Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice," <u>J. Infect. Dis.</u> , 171:18-25 Abstract (1995).	<input type="checkbox"/>
	891	CASADESUS et al., "The Estrogen Myth: Potential Use of Gonadotropin-Releasing Hormone Agonists for the Treatment of Alzheimer's Disease," <u>Drugs R D</u> , 7(3):187-193 (2006).	<input type="checkbox"/>
	901	CASEY, S.O., "Posterior Reversible Encephalopathy Syndrome: Utility of Fluid-attenuated Inversion Recovery MR Imaging in the Detection of Cortical and Subcortical Lesions," <u>Amer J Neuroradiol</u> , 21:1199-1206 (2000).	<input type="checkbox"/>
	932	CHAKRABARTI et al., "Vaccinia Virus Expression Vector: Coexpression of B-Galactosidase Provides Visual Screening of Recombinant Virus Plaques," <u>Molecular and Cellular Biology</u> , 5(12):3403-3409 (1985).	<input type="checkbox"/>

Examiner Signature	Date Considered
-----------------------	--------------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		<i>Application Number</i>	10/828,548
		<i>Filing Date</i>	April 19, 2004
		<i>First Named Inventor</i>	Schenk, Dale B.
		<i>Art Unit</i>	1649
		<i>Examiner Name</i>	Daniel E. Kolker
		<i>Attorney Docket Number</i>	15270J-004747US
Sheet	3	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	930	CHANG et al., "Adjuvant activity of incomplete Freund's adjuvant," <u>Advanced Drug Delivery Reviews</u> , 32:173-186 (1998).	<input type="checkbox"/>
	925	Colombian Patent Application No. 98071271, Technical Opinion of Jean Paul Vernot submitted on June 22, 2005 as evidence with the brief amending the nullity action (with English translation) (drafted November 2004).	<input type="checkbox"/>
	908	COREY-BLOOM et al., "Clinical features distinguishing large cohorts with possible AD, probable AD, and mixed dementia," <u>J. Am. Geriatr. Soc.</u> , 41(1):31-37 Abstract (1993).	<input type="checkbox"/>
	893	DE LA CRUZ et al., "Immunogenicity [sic] and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage," <u>J Biol Chem</u> , 263(9):4318-4322 (1988).	<input type="checkbox"/>
	910	DREW et al., "Vaccination by cholera toxin conjugated to a herpes simplex virus type 2 glycoprotein D peptide," <u>Journal of General Virology</u> , 73:2357-2366 (1992).	<input type="checkbox"/>
	920	Ecuador Patent Application No. SP 98-2764, English translation of Expert Report submitted April 19, 2007 in support of the Appeal filed on July 29, 2005.	<input type="checkbox"/>
	942	European Examination Report of 03/09/2007 for European Application 01995364.5-1222.	<input type="checkbox"/>
	941	European Examination Report of 09/26/2007 for European Application 04720353.4-1222.	<input type="checkbox"/>
	940	European Examination Report of 10/08/2007 for European Application 01995364.5-1222.	<input type="checkbox"/>
	902	GILMAN, S. et al., "Clinical Effects of A β Immunization (AN1792) in Patients with AD in an Interrupted Trial," <u>Neurology</u> , 64:1553-1562 (2005).	<input type="checkbox"/>
	896	GROSS et al., "Microvascular specializations promoting rapid interstitial solute dispersion in nucleus tractus solitarius," <u>Am J Physiol Regul Integr Comp Physiol</u> , 259:R1131-R1138 (1990).	<input type="checkbox"/>
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete if Known Application Number 10/828,548 Filing Date April 19, 2004 First Named Inventor Schenk, Dale B. Art Unit 1649 Examiner Name Daniel E. Kolker Attorney Docket Number 15270J-004747US	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			
Sheet	4	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	931	HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , page 98 (1998).	<input type="checkbox"/>
	887	IDUSOGIE et al., "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," <i>J. Immunology</i> , 164:4178-4184 (2000).	<input type="checkbox"/>
	929	JANSEN et al., "Use of Highly Encapsulated <i>Streptococcus pneumoniae</i> Strains in a Flow-Cytometric Assay for Assessment of the Phagocytic Capacity of Serotype-Specific Antibodies," <i>Clinical & Diagnostic Lab. Immunol.</i> , 5(5):703-710 (1998).	<input type="checkbox"/>
	895	KHATOON et al., "Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer's disease and control brains," <i>FEBS Letters</i> , 351:80-84 (1994).	<input type="checkbox"/>
	888	KUBY, J., eds., pages 108-109, 131-132 from <i>Immunology, Third Edition</i> , W.H. Freeman & co., (1997).	<input type="checkbox"/>
	889	LIU et al., "Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis," <i>Proc. Natl. Acad. Sci.</i> , 95:13266-13271 (1998).	<input type="checkbox"/>
	904	MAMIKONYAN et al., "Anti-A β_{1-11} Antibody Binds to Different β -Amyloid Species, Inhibits Fibril Formation, and Disaggregates Preformed Fibrils but Not the Most Toxic Oligomers," <i>J. Biol. Chem.</i> , 282(31) 22376-22386 (2007).	<input type="checkbox"/>
	913	MANNING et al., "Genetic Immunization with Adeno-Associated Virus Vectors Expressing Herpes Simplex Virus Type 2 Glycoproteins B and D," <i>Journal of Virology</i> , 71(10):7960-7962 (1997).	<input type="checkbox"/>
	886	MORGAN et al., "The N-terminal end of the C γ 2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc γ RII and Fc γ RIII binding," <i>Immunology</i> , 86:319-324 (1995).	<input type="checkbox"/>
	933	PCT International Preliminary Examination Report of 02/09/2004 for application PCT/US01/46587.	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			<i>Application Number</i>	10/828,548
			<i>Filing Date</i>	April 19, 2004
			<i>First Named Inventor</i>	Schenk, Dale B.
			<i>Art Unit</i>	1649
			<i>Examiner Name</i>	Daniel E. Kolker
			<i>Attorney Docket Number</i>	15270J-004747US
Sheet	5	of	6	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published.	T ²
	919	PCT Written Opinion of 12/14/04 for application PCT/US04/02856.	<input type="checkbox"/>
	937	PCT International Preliminary Report on Patentability (Chapter I) of 09/16/2005 with Written Opinion of 05/09/2005 for application PCT/US04/007503.	<input type="checkbox"/>
	938	PCT International Preliminary Report on Patentability (Chapter II) of 04/27/2006 for application PCT/US04/007503.	<input type="checkbox"/>
	903	PCT Search Report of 10/01/2007 and Written Opinion of 10/01/2007 for application PCT/US07/09499.	<input type="checkbox"/>
	890	PEREZ et al., "The β -Amyloid Precursor Protein of Alzheimer's Disease Enhances Neuron Viability and Modulates Neuronal Polarity," <i>J. Neurosci.</i> , 17(24):9407-9414 (1997).	<input type="checkbox"/>
	928	RAMMENSEE, H.G., "Chemistry of peptides associated with MHC class I and class II molecules," <i>Current Opinion in Immunology</i> , 7:85-96 (1995).	<input type="checkbox"/>
	926	RODRIGUEZ et al., "Enfermedad de Alzheimer. Situación Actual y Estrategias Terapéuticas" (Alzheimer Disease: present situation and therapeutic strategies), <i>Rev Cubana Med</i> [online], 38(2):134-142 (1999).	<input type="checkbox"/>
	856	SEUBERT et al., "Antibody Capture of Soluble A β does not Reduce Cortical A β Amyloidosis in the PDAPP Mouse," <i>Neurodegenerative Diseases</i> , 5:65-71 (2008).	<input type="checkbox"/>
	950	SOLOMON et al., "Fast induction of anti- β -amyloid peptide immune response," <i>Research and Practice in Alzheimer's Disease</i> , 6:260-264 (2002).	<input type="checkbox"/>
	914	SPELLERBERG et al., "DNA Vaccines Against Lymphoma," <i>Journal of Immunology</i> , 159:1885-1892 (1997).	<input type="checkbox"/>
	939	Supplementary Partial European Search Report of 04/10/2007 for European Application 04720353.4-1222.	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/828,548
		Filing Date	April 19, 2004
		First Named Inventor	Schenk, Dale B.
		Art Unit	1649
		Examiner Name	Daniel E. Kolker
		Attorney Docket Number	15270J-004747US
Sheet	6	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	907	TANG et al., "Genetic immunization is a simple method for eliciting an immune response," <u>Nature</u> , 356:152-154 (1992).	<input type="checkbox"/>
	936	VANDERSTICHELE et al., "Standardization of Measurement of B-amyloid(1-42) in Cerebrospinal Fluid and Plasma," <u>Int. J. Exp. Clin. Invest.</u> , 7(4):245-258 (2000).	<input type="checkbox"/>
	916	WINBLAD et al., "Hints of a therapeutic Vaccine for Alzheimer's?" <u>Neuron</u> , 38:517-519 (2003).	<input type="checkbox"/>
	897	WHITCOMB et al., "Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain," <u>Am J Physiol Gastrointest Liver Physiol</u> , 259:G687-G691 (1990).	<input type="checkbox"/>
	894	WU et al., "Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of <i>Salmonella</i> ," <u>PNAS</u> , 86:4726-4730 (1989).	<input type="checkbox"/>
	900	Wyeth, Annual Review 2005: Creating Value...Advancing Health (February 27, 2006).	<input type="checkbox"/>
	909	XIANG et al., "Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines," <u>Immunity</u> , 2(2):129-135 Abstract (1995).	<input type="checkbox"/>
	917	YANKNER et al., "Neurotrophic and Neurotoxic effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides," <u>Science</u> , 250:279-282 (1990).	<input type="checkbox"/>
	793	ZAMEER et al., "Single Chain Fv Antibodies against 25-35 Peptide Fragment of Amyloid- β : Potential Therapeutic for Alzheimer's Disease," Abstract P4-420, Page S583, presented at Poster Session P4:Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based, also <u>Neurobiology of Aging</u> , 25(Suppl. 2): p S593 (July 2004).	<input type="checkbox"/>

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.